GlassScriptPhysician profile
Jim R Wade
NPI 1700860913
$3,498.69
in general payments reported to CMS, 2019-2025
32 companies · $580 in 2025
The $580 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $404 · 2021: $488 · 2022: $640 · 2023: $602 · 2024: $430 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,612.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $527.78 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $500.82 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $379.14 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $249.65 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $192.73 | 2019-2025 | Trintellix |
| Amgen INC. | $177.88 | 2019-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $156.31 | 2019-2022 | |
| Glaxosmithkline, LLC. | $152.33 | 2019-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.82 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $129.92 | 2019-2025 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $125.61 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $104.81 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.23 | 2019-2024 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $69.76 | 2020-2022 | |
| Lundbeck LLC | $54.71 | 2024-2025 | Rexulti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $49.56 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $48.41 | 2023 | Quviviq |
| Biogen, INC. | $40.68 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.24 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $33.90 | 2025 | Gardasil 9, Capvaxive |
| Allergan, INC. | $29.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.88 | 2024 | |
| Sanofi-Aventis U.S. LLC | $22.18 | 2020 | |
| Medtronic, INC. | $21.93 | 2024 | Intellis Adaptivestim |
| Abbott Laboratories | $20.97 | 2024 | Freestyle Libre 3 |
| Dexcom, INC. | $17.48 | 2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $16.64 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $15.95 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.29 | 2019 | |
| Esperion Therapeutics, INC. | $13.96 | 2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $12.74 | 2019 | |
| Sunovion Pharmaceuticals INC. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jim Wade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.